Orismilast is under clinical development by Union Therapeutics and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Orismilast’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Orismilast (UNI-50001) is under development for the treatment of psoriasis vulgaris, mild, moderate or severe hidradenitis suppurativa (HS), ulcerative colitis and moderate atopic dermatitis (AD). It is a small molecule administered orally. It acts by targeting phosphodiesterase 4 (PDE4 B/D). It is developed as immediate and modified release formulations.
Union Therapeutics overview
Union Therapeutics is a privately held, clinical stage, pharmaceutical and healthcare company that offers development of a novel class of antibiotics. The company’s lead products are orismilast (UNI5001), niclosamide (UNI50002) and Topical oxyclozanide. Union Therapeutics pipeline products are used in treating psoriasis,atopic dermatitis, hidradenitis suppurativa, covid -19 prophylaxis, canine pyoderma and veterinary programs. It provides its products under the brand humira (adalimumab). The company involves in the treatment of skin infections and microbiome-related dermatological disorders. Its products are being developed for the treatment of canine pyoderma mostly found in animals. Union Therapeutics is headquartered in Copenhagen, Denmark.
For a complete picture of Orismilast’s drug-specific PTSR and LoA scores, buy the report here.